NAPLES, Fla., and MUMBAI, India — Vinita Gupta, chief executive officer of Lupin Limited, has been named to the 2026 CNBC Changemakers list of Women Transforming Business, recognizing leaders who are driving innovation and reshaping their industries.
The annual CNBC Changemakers list honors women whose leadership is delivering measurable business impact and long-term change. Gupta was recognized for her work expanding access to affordable medicines in the United States and globally.
“I am honored to be recognized as a CNBC Changemaker and listed amongst such extraordinary leaders who are driving significant change and impact,” Gupta said. “This recognition reflects not only my own journey, but the shared dedication of everyone at Lupin who works each day to help transform hope into healing. I truly believe that meaningful change occurs when purpose is matched by execution.”
Gupta built Lupin’s U.S. business from the ground up. During her tenure, the company has grown into the third-largest generic medicine supplier in the United States and the world’s seventh-largest pharmaceutical company by volume. Under her leadership, Lupin has expanded its portfolio to include complex generics, inhalation products, and biosimilars.
In late 2025, Lupin received U.S. Food and Drug Administration approval for its first biosimilar, pegfilgrastim, marking a milestone in the company’s strategy to broaden access to high-quality, lower-cost biologic medicines.
Gupta has also prioritized domestic manufacturing. In 2025, Lupin advanced a reshoring initiative and announced plans for a new inhalation manufacturing facility in Coral Springs, Fla., expected to produce multiple respiratory products, including albuterol. The investment is aimed at strengthening U.S. medicine security and improving patient access.
CNBC Changemakers honorees will be recognized at the CNBC Changemakers Summit on April 16 in New York.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
